Healthcare & Pharmaceuticals

A Major Year for the Water Industry – 2019 by Durrat Adnan

The reviewed business plans for 2020 to 2025 promise dynamic and passionate strategies delivering real benefits to customers, the environment and the country as a whole. “The next decade will see profound changes in customers’ expectations and we are pushing the water sector to be at the forefront of that” announced Ofwat (Office of Water…

Read More

Antibiotic resistance as a Global Threat by Aram Andreasyan

For the past decade, antibiotic resistance (ABR) has become an increasingly threatful and potentially disastrous global issue. The high use of antibiotics world-wide, emergence and rapid spreading of multidrug-resistant bacteria and lack of innovative and effective antibiotics resulted in a fast-impending menace for health systems and global development. ABR is currently responsible for 700,000 deaths…

Read More

Genentech acquires Jecure Therapeutics by Malaviga Gopalakrishnan

Genentech (a subsidiary of Roche), a research-based biotechnological company, has acquired Jecure Therapeutics. Jecure specialised in drug discovery programs targeting inflammatory disorders, with a significant development in the preclinical portfolio of NLRP3 inhibitors to fight these disorders. No financial terms were disclosed, but a Genentech spokesman said it was an all-cash deal. Due to this…

Read More

Catalyst Pharmaceuticals: why is the stock falling? By Aram Andreasyan

Catalyst Pharmaceuticals is an American biopharmaceutical company based in Florida. The company is developing therapeutics for rare neurological diseases, including the phosphate salt of amifampridine for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) under the trade name “Firdapse”. LEMS is a rare autoimmune disorder affecting one in every 300,000 people. The condition’s main symptoms are…

Read More

Marijuana Stocks: An Overview and Future Prospects by Prince Soni

On 20th June 2018, Justin Trudeau, Prime Minister of Canada, announced the legalization of recreational marijuana in the country starting 17th Oct 2018. Following this announcement, there was an obvious hope for investors to benefit from this potential marijuana market boom, which did occur. Between 20th June and 15th Oct, Canopy Growth Corp (CGC), Canada’s…

Read More

Pharma Meets Social Media: Untapped Potential by Estia Ryan

The pharmaceutical industry isn’t traditionally thought of as embracing social media for change. A recent study however shows the huge potential for the market: 80% of social media users also look for health information online. 90% of 18-24 year-olds rely on social media in some form to educate themselves on health. Social media however goes…

Read More

High Time for European Pharmaceuticals: Changing Medical-Cannabis Regulation by Estia Ryan

Six new countries have announced medical legalization in 2018 alone. This now means 22 countries in the region allow cannabis-derived medicines. The boundaries between legal and illegal drugs are usually quite blurred – and any changes in the regulatory landscape should excite investors. Earlier this summer, Sajid Javid relaxed UK rules concerning cannabis-derived medicines after…

Read More